HCA Healthcare, Inc. (HCA) — Fair Value Analysis

Base-case fair value (P50): $544.31 · Current price: $396.94 · Verdict: Undervalued

The Verdict on HCA

HCA Healthcare (HCA) currently appears Deeply Undervalued based on our latest Monte Carlo simulations, which project a median fair value (P50) of $544.31. This stands in stark contrast to the current market price of $396.94, indicating a significant potential upside of +37.1%. Our analysis, rooted in thousands of forward-looking scenarios, suggests that HCA's intrinsic value is substantially higher than its trading price. This robust, simulation-driven verdict provides a clear, data-backed perspective for investors evaluating the healthcare giant, effectively answering whether HCA is overvalued: it is not. The discrepancy between $396.94 and $544.31 signals a compelling valuation opportunity.

How HCA stacks up against Healthcare

When assessing HCA's position within the broader Healthcare sector, its operational and financial health is rated as an average quality tier. This designation suggests HCA maintains a stable, competitive footing, demonstrating solid performance relative to its peers. Despite this average quality tier, the substantial upside of +37.1% from its $396.94 to the median fair value of $544.31 is particularly noteworthy. While some sector peers might boast marginally higher quality metrics, HCA's current valuation disconnect, as revealed by our comprehensive Monte Carlo simulations, points to an attractive risk-reward profile. The analysis indicates its fair value reflects a specific, identifiable undervaluing even for an average quality company.

What this means for investors

For investors evaluating HCA, the current market price of $396.94 presents a compelling entry point relative to the Monte Carlo derived median fair value of $544.31. The projected +37.1% indicates a strong potential return should the market re-rate the stock closer to its intrinsic value. While all investments carry inherent risk, and various downside scenarios always exist, our simulations suggest a significant margin of safety at the current price, coupled with robust upside potential. HCA's average quality tier further solidifies its position as a fundamentally sound company benefiting from a clear valuation gap. To explore the full distribution of bear-case and bull-case targets, and track HCA's fair value as new fundamentals are released, sign up for a free FairCurve account.